The widely available blood thinner apixaban substantially reduced stroke in at-risk patients with a type of atrial fibrillation only detectable by a pacemaker or other implanted cardiac electronic device, the new ARTESiA study has found.
The global study, co-led by Jeff Healey, PHRI Senior Scientist, and Renato Lopes, professor in the Department of Medicine at Duke University School of Medicine, shows the oral anticoagulant medication, which helps to prevent dangerous blood clots by thinning the blood, reduced the risk of stroke and blood clotting by 37 per cent and reduced fatal or disabling stroke by 49 per cent in individuals with device-detected atrial fibrillation, also known as sub-clinical atrial fibrillation (SCAF). This condition is not easily detectable through standard tests like electrocardiograms, unlike clinical atrial fibrillation.
The study was published on November 12 in the New England Journal of Medicine (NEJM) and simultaneously presented at the American Heart Association Scientific Sessions by Healey, co-principal investigator (PI) and first author of the study.
— European Society of Cardiology (@escardio) November 12, 2023
Healey and a global team of researchers conducted the largest and longest-running study of apixaban for people with device-detected atrial fibrillation. The ARTESiA study involved more than 4,000 participants at 288 sites in 16 countries over eight years.
“While we found an increase in major bleeding, this non-fatal bleeding is usually reversible and most patients recover from it,” says Healey.
“Considering how much more severe and life-altering the strokes prevented by apixaban are, compared to most cases of bleeding, our findings indicate that apixaban should be considered for patients with stroke risk factors who develop device-detected atrial fibrillation,” says Stuart Connolly, a PHRI senior scientist, chair and senior author of the publication.
Renato Lopes, co-PI of the study, says, “our findings can aid doctors in treating these patients, so they don’t suffer disabling and fatal strokes.” This global trial was an academic collaboration between the Duke Clinical Research Institute and PHRI, leading research institutes in the area of cardiology and clinical trials.
In the rapidly evolving landscape of cardiac monitoring, Healey underscores the study’s far-reaching impact.
“Our findings also have a broader significance,” Healey notes, “as we witness the increasing use of implanted and wearable cardiac monitors, along with consumer devices like the Apple Watch. A future where more at-risk individuals are identified and receive effective stroke prevention treatment is on the horizon.”
It was an honor to lead this study with my good friend Jeff Healey. What a journey – 8 years to get this done. But with an amazing team of investigators highly committed to the trial from 247 sites/16countries we did. Nice to see a clear answer to an important clinical question! https://t.co/Q4qrWnXpuW
— Renato D Lopes (@RenatoDLopes1) November 14, 2023
The ARTESiA team we would like to thank all of our study personnel for your hard work over these past few months! Congratulations on helping us reach this significant moment in the study! @Artesia_RCT@PHRIresearch pic.twitter.com/yoO3coARIN
— The ARTESiA Trial 🇨🇦 (@Artesia_RCT) October 30, 2023
The study was funded by the Canadian Institutes for Health Research, the Bristol-Myers Squibb-Pfizer Alliance, the Heart and Stroke Foundation of Canada, the Canadian Stroke Prevention Intervention Network (CSPIN), Hamilton Health Sciences, the Advancing Clinical Trials (ACT) Network and the Population Health Research Institute.